CLGN
CollPlant Biotechnologies Ltd.
Price Chart
Latest Quote
$0.34
+0.00 (+0.03%)
Current Price
| Previous Close | $0.34 |
| Open | $0.34 |
| Day High | $0.34 |
| Day Low | $0.32 |
| Volume | 15,756 |
Stock Information
| Shares Outstanding | 14.42M |
| Total Debt | $2.65M |
| Cash Equivalents | $4.26M |
| Revenue | $389K |
| Net Income | $-13.13M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.86M |
| EPS (TTM) | $-1.04 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.22M |
| Sales | $389K |
| Income | $-13.13M |
| Book/sh | $0.34 |
| Cash/sh | $0.30 |
| Employees | 39 |
Financial Ratios
| Quick Ratio | 1.84 |
| Current Ratio | 2.27 |
| Debt/Eq | 54.22 |
Returns & Margins
| ROA | -61.34% |
| ROE | -151.99% |
| Gross Margin | -147.56% |
| Operating Margin | -4267.12% |
Ownership
| Insider Ownership | 26.87% |
| Institutional Ownership | 12.03% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.86 |
| P/S | 12.50 |
| P/B | 0.99 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.38 |
| SMA50 | $0.39 |
| SMA200 | $1.34 |
| RSI | 11.76 |
| ATR | 0.0395 |
| Shares Float | 10.15M |
| Short Float | 0.40% |
| Short Ratio | 0.73 |
| Volatility | 0.64 |
| Rel Volume | 0.20 |
Performance History
| Week | +0.90% |
| Month | -19.76% |
| Quarter | -44.75% |
| 6 Months | -77.97% |
| YTD | -77.23% |
| Year | -78.40% |
| 3 Years | -95.36% |
| 5 Years | -98.00% |
| 10 Years | -96.23% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.34 | 16,800 |
| 2026-06-17 | $0.34 | 46,900 |
| 2026-06-16 | $0.34 | 116,900 |
| 2026-06-15 | $0.33 | 266,200 |
| 2026-06-12 | $0.34 | 518,400 |
| 2026-06-11 | $0.33 | 23,600 |
| 2026-06-10 | $0.36 | 17,800 |
| 2026-06-09 | $0.37 | 44,500 |
| 2026-06-08 | $0.37 | 20,400 |
| 2026-06-05 | $0.37 | 39,900 |
| 2026-06-04 | $0.40 | 57,300 |
| 2026-06-03 | $0.40 | 69,700 |
| 2026-06-02 | $0.40 | 16,900 |
| 2026-06-01 | $0.40 | 120,500 |
| 2026-05-29 | $0.40 | 150,100 |
| 2026-05-28 | $0.41 | 38,900 |
| 2026-05-27 | $0.41 | 44,800 |
| 2026-05-26 | $0.41 | 7,400 |
| 2026-05-22 | $0.43 | 15,000 |
| 2026-05-21 | $0.42 | 33,800 |
| 2026-05-20 | $0.45 | 12,000 |
| 2026-05-19 | $0.42 | 9,500 |
About CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
đ° Latest News
When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Turn A Profit?
Simply Wall St. âĸ 2026-02-08T12:45:43Z
CollPlant to sell 1.6M ordinary shares at $1.25 in registered direct offering
TipRanks âĸ 2026-02-06T13:06:22Z
Here's Why We're A Bit Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
Simply Wall St. âĸ 2025-11-13T10:13:31Z
One CollPlant Biotechnologies Insider Raised Their Stake In The Previous Year
Simply Wall St. âĸ 2025-10-03T10:47:05Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $835,000 | $1,625,000 | $1,991,000 | $400,000 |
| Cost Of Revenue | $835,000 | $1,625,000 | $1,991,000 | $400,000 |
| Total Revenue | $2,371,000 | $515,000 | $10,959,000 | $299,000 |
| Operating Revenue | $2,371,000 | $515,000 | $10,959,000 | $299,000 |
| Expenses | ||||
| Total Expenses | $13,854,000 | $17,766,000 | $18,471,000 | $17,396,000 |
| Other Income Expense | $-371,000 | $-79,000 | $-285,000 | $-115,000 |
| Net Non Operating Interest Income Expense | $365,000 | $721,000 | $778,000 | $287,000 |
| Total Other Finance Cost | $15,000 | $17,000 | $10,000 | $34,000 |
| Operating Expense | $13,019,000 | $16,141,000 | $16,480,000 | $16,996,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,489,000 | $-16,609,000 | $-7,019,000 | $-16,925,000 |
| Net Interest Income | $365,000 | $721,000 | $778,000 | $287,000 |
| Interest Income | $380,000 | $738,000 | $788,000 | $321,000 |
| Normalized Income | $-11,118,000 | $-16,530,000 | $-6,734,000 | $-16,810,000 |
| Net Income From Continuing And Discontinued Operation | $-11,489,000 | $-16,609,000 | $-7,019,000 | $-16,925,000 |
| Total Operating Income As Reported | $-11,483,000 | $-17,251,000 | $-7,512,000 | $-17,097,000 |
| Net Income Common Stockholders | $-11,489,000 | $-16,609,000 | $-7,019,000 | $-16,925,000 |
| Net Income | $-11,489,000 | $-16,609,000 | $-7,019,000 | $-16,925,000 |
| Net Income Including Noncontrolling Interests | $-11,489,000 | $-16,609,000 | $-7,019,000 | $-16,925,000 |
| Net Income Continuous Operations | $-11,489,000 | $-16,609,000 | $-7,019,000 | $-16,925,000 |
| Pretax Income | $-11,489,000 | $-16,609,000 | $-7,019,000 | $-16,925,000 |
| Interest Income Non Operating | $380,000 | $738,000 | $788,000 | $321,000 |
| Operating Income | $-11,483,000 | $-17,251,000 | $-7,512,000 | $-17,097,000 |
| Gross Profit | $1,536,000 | $-1,110,000 | $8,968,000 | $-101,000 |
| Per Share | ||||
| Diluted EPS | $-0.94 | $-1.45 | $-0.62 | $-1.53 |
| Basic EPS | $-0.94 | $-1.45 | $-0.62 | $-1.53 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-10,200,000 | $-16,134,000 | $-6,125,000 | $-15,906,000 |
| Total Unusual Items | $-371,000 | $-79,000 | $-285,000 | $-115,000 |
| Total Unusual Items Excluding Goodwill | $-371,000 | $-79,000 | $-285,000 | $-115,000 |
| Reconciled Depreciation | $912,000 | $1,038,000 | $1,102,000 | $1,076,000 |
| EBITDA (Bullshit earnings) | $-10,571,000 | $-16,213,000 | $-6,410,000 | $-16,021,000 |
| EBIT | $-11,483,000 | $-17,251,000 | $-7,512,000 | $-17,097,000 |
| Diluted Average Shares | $12,203,269 | $11,454,180 | $11,389,168 | $11,033,310 |
| Basic Average Shares | $12,203,269 | $11,454,180 | $11,389,168 | $11,033,310 |
| Diluted NI Availto Com Stockholders | $-11,489,000 | $-16,609,000 | $-7,019,000 | $-16,925,000 |
| Gain On Sale Of Security | $-371,000 | $-79,000 | $-285,000 | $-115,000 |
| Research And Development | $8,187,000 | $10,515,000 | $10,484,000 | $10,255,000 |
| Selling General And Administration | $4,832,000 | $5,626,000 | $5,996,000 | $6,741,000 |
Fetched: 2026-06-12
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $6,008,000 | $13,334,000 | $28,152,000 | $32,036,000 |
| Total Assets | $10,785,000 | $18,710,000 | $34,126,000 | $37,768,000 |
| Total Non Current Assets | $4,038,000 | $5,530,000 | $6,104,000 | $6,110,000 |
| Other Non Current Assets | $76,000 | $118,000 | $57,000 | $188,000 |
| Goodwill And Other Intangible Assets | $73,000 | $131,000 | $188,000 | $245,000 |
| Current Assets | $6,747,000 | $13,180,000 | $28,022,000 | $31,658,000 |
| Restricted Cash | $359,000 | $248,000 | $241,000 | $23,000 |
| Inventory | $573,000 | $440,000 | $714,000 | $1,430,000 |
| Receivables | $224,000 | $583,000 | $393,000 | $552,000 |
| Other Receivables | $223,000 | $433,000 | $393,000 | $543,000 |
| Accounts Receivable | $1,000 | $150,000 | $0 | $9,000 |
| Cash Cash Equivalents And Short Term Investments | $5,591,000 | $11,909,000 | $26,674,000 | $29,653,000 |
| Cash And Cash Equivalents | $5,591,000 | $11,909,000 | $26,674,000 | $29,653,000 |
| Debt | ||||
| Total Debt | $2,846,000 | $3,081,000 | $3,159,000 | $2,911,000 |
| Long Term Debt And Capital Lease Obligation | $2,032,000 | $2,275,000 | $2,535,000 | $2,382,000 |
| Current Debt And Capital Lease Obligation | $814,000 | $806,000 | $624,000 | $529,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,704,000 | $5,245,000 | $5,786,000 | $5,487,000 |
| Total Non Current Liabilities Net Minority Interest | $2,032,000 | $2,275,000 | $2,535,000 | $2,382,000 |
| Current Liabilities | $2,672,000 | $2,970,000 | $3,251,000 | $3,105,000 |
| Payables And Accrued Expenses | $672,000 | $971,000 | $1,085,000 | $1,186,000 |
| Payables | $672,000 | $971,000 | $980,000 | $1,186,000 |
| Other Payable | $62,000 | $101,000 | $105,000 | $53,000 |
| Accounts Payable | $610,000 | $870,000 | $980,000 | $1,133,000 |
| Current Deferred Liabilities | - | - | - | $0 |
| Derivative Product Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $6,081,000 | $13,465,000 | $28,340,000 | $32,281,000 |
| Total Equity Gross Minority Interest | $6,081,000 | $13,465,000 | $28,340,000 | $32,281,000 |
| Stockholders Equity | $6,081,000 | $13,465,000 | $28,340,000 | $32,281,000 |
| Gains Losses Not Affecting Retained Earnings | $-969,000 | $-969,000 | $-969,000 | $-969,000 |
| Other Equity Adjustments | $-969,000 | $-969,000 | $-969,000 | $-969,000 |
| Retained Earnings | $-124,839,000 | $-113,350,000 | $-96,741,000 | $-89,722,000 |
| Other | ||||
| Treasury Shares Number | $18,409 | $18,409 | $18,409 | - |
| Ordinary Shares Number | $12,803,006 | $11,454,512 | $11,452,672 | $11,186,481 |
| Share Issued | $12,821,415 | $11,472,921 | $11,471,081 | $11,186,481 |
| Tangible Book Value | $6,008,000 | $13,334,000 | $28,152,000 | $32,036,000 |
| Invested Capital | $6,081,000 | $13,465,000 | $28,340,000 | $32,281,000 |
| Working Capital | $4,075,000 | $10,210,000 | $24,771,000 | $28,553,000 |
| Capital Lease Obligations | $2,846,000 | $3,081,000 | $3,159,000 | $2,911,000 |
| Total Capitalization | $6,081,000 | $13,465,000 | $28,340,000 | $32,281,000 |
| Additional Paid In Capital | $126,397,000 | $122,801,000 | $121,068,000 | $118,099,000 |
| Capital Stock | $5,492,000 | $4,983,000 | $4,982,000 | $4,873,000 |
| Common Stock | $5,492,000 | $4,983,000 | $4,982,000 | $4,873,000 |
| Long Term Capital Lease Obligation | $2,032,000 | $2,275,000 | $2,535,000 | $2,382,000 |
| Current Capital Lease Obligation | $814,000 | $806,000 | $624,000 | $529,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,186,000 | $1,193,000 | $1,542,000 | $1,390,000 |
| Net PPE | $3,889,000 | $5,281,000 | $5,859,000 | $5,677,000 |
| Accumulated Depreciation | $-7,878,000 | $-7,024,000 | $-6,046,000 | $-5,041,000 |
| Gross PPE | $11,767,000 | $12,305,000 | $11,905,000 | $10,718,000 |
| Leases | $3,660,000 | $3,650,000 | $3,503,000 | $3,310,000 |
| Other Properties | $7,232,000 | $7,783,000 | $7,589,000 | $6,626,000 |
| Machinery Furniture Equipment | $875,000 | $872,000 | $813,000 | $782,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $290,000 | $154,000 | $541,000 | $549,000 |
| Work In Process | $283,000 | $286,000 | $173,000 | $881,000 |
| Current Accrued Expenses | - | $101,000 | $105,000 | $944,000 |
| Foreign Currency Translation Adjustments | - | - | - | $-969,000 |
| Current Deferred Revenue | - | - | - | $0 |
| Current Provisions | - | - | - | $446,000 |
| Other Short Term Investments | - | - | - | $0 |
Fetched: 2026-06-12
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-9,447,000 | $-14,576,000 | $-3,717,000 | $-15,014,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,419,000 | $-14,093,000 | $-2,763,000 | $-13,698,000 |
| Cash Flow From Continuing Operating Activities | $-9,419,000 | $-14,093,000 | $-2,763,000 | $-13,698,000 |
| Operating Gains Losses | $-80,000 | $142,000 | $397,000 | $608,000 |
| Investing Activities | ||||
| Capital Expenditure | $-28,000 | $-483,000 | $-954,000 | $-1,316,000 |
| Investing Cash Flow | $-27,000 | $-539,000 | $-1,156,000 | $28,922,000 |
| Cash Flow From Continuing Investing Activities | $-27,000 | $-539,000 | $-1,156,000 | $28,922,000 |
| Net Other Investing Changes | - | $-57,000 | $-270,000 | - |
| Capital Expenditure Reported | - | - | - | $-42,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,102,000 | $0 | $0 | $0 |
| Financing Cash Flow | $3,102,000 | $9,000 | $1,108,000 | $1,874,000 |
| Cash Flow From Continuing Financing Activities | $3,102,000 | $9,000 | $1,108,000 | $1,874,000 |
| Net Common Stock Issuance | $3,102,000 | $0 | $0 | $0 |
| Common Stock Issuance | $3,102,000 | $0 | $0 | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $16,000 | $62,000 | $8,000 | $31,000 |
| End Cash Position | $5,591,000 | $11,909,000 | $26,674,000 | $29,864,000 |
| Beginning Cash Position | $11,909,000 | $26,674,000 | $29,864,000 | $13,374,000 |
| Effect Of Exchange Rate Changes | $26,000 | $-142,000 | $-379,000 | $-608,000 |
| Changes In Cash | $-6,344,000 | $-14,623,000 | $-2,811,000 | $17,098,000 |
| Proceeds From Stock Option Exercised | $0 | $9,000 | $1,108,000 | $1,874,000 |
| Net PPE Purchase And Sale | $-27,000 | $-482,000 | $-886,000 | $-1,274,000 |
| Sale Of PPE | $1,000 | $1,000 | $68,000 | $0 |
| Purchase Of PPE | $-28,000 | $-483,000 | $-954,000 | $-1,274,000 |
| Change In Working Capital | $254,000 | $-372,000 | $848,000 | $-544,000 |
| Change In Other Current Liabilities | $-336,000 | $-650,000 | $-638,000 | $-916,000 |
| Change In Other Current Assets | $666,000 | $651,000 | $527,000 | $461,000 |
| Change In Payables And Accrued Expense | $-306,000 | $-463,000 | $51,000 | $113,000 |
| Change In Accrued Expense | $-46,000 | $-353,000 | $204,000 | $14,000 |
| Change In Payable | $-260,000 | $-110,000 | $-153,000 | $99,000 |
| Change In Account Payable | $-260,000 | $-110,000 | $-153,000 | $99,000 |
| Change In Inventory | $-129,000 | $280,000 | $749,000 | $-312,000 |
| Change In Receivables | $359,000 | $-190,000 | $159,000 | $142,000 |
| Changes In Account Receivables | $149,000 | $-150,000 | $9,000 | $261,000 |
| Other Non Cash Items | $-15,000 | $-11,000 | $-28,000 | $-87,000 |
| Stock Based Compensation | $999,000 | $1,719,000 | $1,937,000 | $2,174,000 |
| Depreciation Amortization Depletion | $912,000 | $1,038,000 | $1,102,000 | $1,076,000 |
| Depreciation And Amortization | $912,000 | $1,038,000 | $1,102,000 | $1,076,000 |
| Net Foreign Currency Exchange Gain Loss | $-80,000 | $142,000 | $379,000 | $608,000 |
| Gain Loss On Sale Of PPE | $0 | $0 | $18,000 | $0 |
| Net Income From Continuing Operations | $-11,489,000 | $-16,609,000 | $-7,019,000 | $-16,925,000 |
| Net Investment Purchase And Sale | - | $0 | $0 | $30,238,000 |
| Sale Of Investment | - | $0 | $0 | $50,238,000 |
| Purchase Of Investment | - | $0 | $0 | $-20,000,000 |
| Net Intangibles Purchase And Sale | - | $0 | $0 | $-42,000 |
| Purchase Of Intangibles | - | $0 | $0 | $-42,000 |
| Change In Prepaid Assets | - | - | $150,000 | $-119,000 |
| Repayment Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | $-32,000 |
| Depreciation | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-12